EXAS · Insider Trading
Exact Sciences Corp
Every open-market purchase and sale reported by EXAS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | Katherine S Zanotti | Director | D | −60,759 | — |
| 2026-03-23 | Michael J Barber | Director | D | −13,136 | — |
| 2026-03-23 | Kimberly J Popovits | Director | D | −16,381 | — |
| 2026-03-23 | Sarah Condella | EVP, Human Resources | MIXED | −137,870 | — |
| 2026-03-23 | Paul J Clancy | Director | D | −26,038 | — |
| 2026-03-23 | Shacey Petrovic | Director | D | −28,899 | — |
| 2026-03-23 | Jacob A Orville | EVP, GM, Screening | MIXED | −102,177 | — |
| 2026-03-23 | Leslie Trigg | Director | D | −17,169 | — |
| 2026-03-23 | James Edward Doyle | Director | D | −57,962 | — |
| 2026-03-23 | D Scott Coward | Director | D | −62,256 | — |
| 2026-03-23 | James Herriott | SVP, General Counsel & Sec | D | −69,957 | — |
| 2026-03-23 | Kevin T Conroy | President and CEO | MIXED | −1,558,202 | — |
| 2026-03-23 | Aaron Bloomer | EVP, Chief Financial Officer | MIXED | −49,185 | — |
| 2026-03-23 | Brian Baranick | EVP, GM, Precision Oncology | MIXED | −104,669 | — |
| 2026-03-03 | Sarah Condella | EVP, Human Resources | MIXED | +1,987 | −$178.15K |
| 2026-03-03 | Kevin T Conroy | President and CEO | MIXED | +36,090 | −$3.30M |
| 2026-02-27 | Aaron Bloomer | EVP, Chief Financial Officer | A | — | — |
| 2026-02-27 | Jacob A Orville | EVP, GM, Screening | A | — | — |
| 2026-02-27 | Sarah Condella | EVP, Human Resources | A | — | — |
| 2026-02-27 | Brian Baranick | EVP, GM, Precision Oncology | A | — | — |
| 2026-02-27 | Kevin T Conroy | President and CEO | MIXED | +6,985 | −$640.98K |
| 2026-02-27 | James Herriott | SVP, General Counsel & Sec | A | — | — |
| 2025-12-30 | Aaron Bloomer | EVP, Chief Financial Officer | MIXED | +35,145 | −$2.85M |
| 2025-12-30 | Brian Baranick | EVP, GM, Precision Oncology | MIXED | +81,506 | −$8.56M |
| 2025-12-30 | Kevin T Conroy | President and CEO | MIXED | +378,382 | −$34.17M |
| 2025-12-30 | Jacob A Orville | EVP, GM, Screening | MIXED | +77,166 | −$6.97M |
| 2025-12-30 | Sarah Condella | EVP, Human Resources | MIXED | +47,288 | −$4.27M |
| 2025-12-30 | James Herriott | SVP, General Counsel & Sec | MIXED | +56,230 | −$5.08M |
| 2025-11-21 | James Herriott | SVP, General Counsel & Sec | Sell | −1,000 | −$70.00K |
| 2025-11-21 | Jacob A Orville | EVP, GM, Screening | Sell | −5,000 | −$375.00K |
| 2025-11-06 | Brian Baranick | EVP, GM, Precision Oncology | Sell | −2,858 | −$200.29K |
| 2025-11-06 | James Herriott | SVP, General Counsel & Sec | Sell | −1,500 | −$105.12K |
| 2025-10-27 | Katherine S Zanotti | Director | Sell | −12,000 | −$780.00K |
| 2025-10-10 | James Edward Doyle | Director | Sell | −2,000 | −$120.00K |
| 2025-10-10 | James Herriott | SVP, General Counsel & Sec | Sell | −1,500 | −$90.00K |
| 2025-08-14 | James Edward Doyle | Director | Sell | −1,485 | −$62.40K |
| 2025-08-07 | Jacob A Orville | EVP, GM, Screening | MIXED | +2,835 | −$117.78K |
| 2025-08-07 | Brian Baranick | EVP, GM, Precision Oncology | MIXED | +2,633 | −$127.24K |
| 2025-06-16 | Michael J Barber | Director | A | +7,197 | — |
| 2025-06-16 | James Edward Doyle | Director | A | +5,398 | — |
| 2025-06-16 | D Scott Coward | Director | A | +5,398 | — |
| 2025-06-16 | Daniel J Levangie | Director | A | +5,398 | — |
| 2025-06-16 | Paul J Clancy | Director | A | +5,398 | — |
| 2025-06-16 | Leslie Trigg | Director | A | +7,670 | — |
| 2025-06-16 | Katherine S Zanotti | Director | MIXED | +2,191 | −$170.61K |
| 2025-06-16 | Shacey Petrovic | Director | A | +5,398 | — |
| 2025-06-16 | Kimberly J Popovits | Director | A | +9,994 | — |
| 2025-05-08 | James Herriott | SVP, General Counsel & Sec | A | +363 | +$13.89K |
| 2025-05-01 | Leslie Trigg | Director | A | +8,527 | — |
| 2025-04-17 | Aaron Bloomer | EVP, Chief Financial Officer | MIXED | +13,623 | −$479.54K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sarah Condella | EVP, Human Resources | 191,891 | $20.13M |
| Brian Baranick | EVP, GM, Precision Oncology | 137,195 | $14.39M |
| Daniel J Levangie | Director | 34,312 | $3.60M |
| Kathleen Sebelius | Director | 32,671 | $3.43M |
| Leslie Trigg | Director | 13,925 | $1.46M |
| Kimberly J Popovits | Director | 9,656 | $1.01M |
| D Scott Coward | Director | 5,398 | $566.30K |
| James Edward Doyle | Director | 5,398 | $566.30K |
| Katherine S Zanotti | Director | 3,739 | $392.26K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EXAS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.